Secondary CNS Lymphoma
Keywords:
-Abstract
-
Downloads
References
DeAngelis LM, Yahalom J, Thaler HT. Combined modality therapy for primary CNS lymphoma. J Clin Oncol 1992;10:635.
DeAngelis LM, Seiferheld W, Seiferheld W, Wchold SC, et al. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 2002;20:4643.
Rubenstein JL, Combs D, Rosenberg J, et al. Rituximab therapy for CNS lymphomas: targeting the Peeptomeningeal compartment. Blood 2003;101:466-8.
Schulz H, Pels H, Schlegel U, et al. Intraventricular application of rituximab as a treatment option in patients with CNS lymphoma and leptomeningeal disease. Proc Amer Clin Oncol 2004;23:112 (abstract).
Young RC, Howser DM, Anderson T, Fisher RI, Jaffe
E, DeVita VT Jr. Central nervous system complications of non-Hodgkin's lymphoma. The potential role of prophylactic therapy. Am J Med 1979;66:435.
Touroutouglou N, Dimopoulos MA, Younes A, Hess M, Pugh W, Cox J, Cabanillas F, Sarris AH. Testicular lymphoma: Late relapses and poor outcome despite doxorubicin-based therapy. J Clin Oncol 1995,13:1361.
Montserrat E, Bosch F, Lopez-Guillermo A, Graus F, Terol MJ, Campo E, Rozman C. CNS involvement in mantle-cell lymphoma. J Clin Oncol 1966;14:941.
Perez-Soler R, Smith TL, Cabanillas F. Central nervous system prophylaxis with combined intravenous and intrathecal methotrexate in diffuse lymphoma of aggressive histologic type. Cancer 1986;57:971.
van Besien K, Ha CS, Murphy S, et al. Risk factors, treatment and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood 1998;91:1178.
Hegde U, Fiter A, Little RF, et al. High incidence of ocult leptomeningeal disease delected by flow cytometry in newly diagnosed aggressive B-cell lymphoma at risk of central nervous system in volvement: the role of flow cytometry versus cytology. Blood 2004 [Epub ahead of print].
Chua SL, Seymour JF, Streater J, Wolf MM, Janusze-wicz EH, Prince HM. Intrathecal chemotherapy is ineffective for central nervous system (CNS) prophylaxis in patients with high-risk intermediate grade non-Hodgkin's lymphoma. Blood 2000:96:728 (abstract).
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
